Drug Trial begins targeting Mitochondrial Diseases: EXCLUSIVE AUDIO INTERVIEW
Print
Is there hope for a cure for Mitochondrial Disease? Perhaps the answer is closer than we thought.
On July 15, 2008 Edison Pharma and partner Penwest Pharmaceuticals announced that A0001, an "improved" variant of Coenzyme Q10 (CoQ10), has entered Phase 1 clinical development with healthy volunteers. Edison predicts trials in patients with inherited mitochondrial disease will begin in 2009.
This Friday, July 18, 2008, Cristy Balcells, Executive Director of MitoAction, conducted an exclusive interview with Dr. Guy Miller, CEO of Edison Pharma.
Listen to the interview here (right click to download as mp3 to iPod/player)
Read the Edison A0001 Press Release here
Thanks for sharing these
Submitted by blizzard on Sat, 05/09/2009 - 12:04am.